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The global coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has made the development of a vaccine a top biomedical
priority. In this study, we developed a series of DNA vaccine candidates expressing different forms
of the SARS-CoV-2 spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated
animals developed humoral and cellular immune responses, including neutralizing antibody titers at
levels comparable to those found in convalescent humans and macaques infected with SARS-CoV-2.
After vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the
full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in
bronchoalveolar lavage and nasal mucosa, respectively, as compared with viral loads in sham
controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting
an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2
in nonhuman primates.
T
he coronavirus disease 2019 (COVID-19)
pandemic has made the development of
a safe, effective, and deployable vaccine
to protect against infection with severe
acute respiratory syndrome coronavirus 2
(SARS-CoV-2) a critical global priority (1–8).
Our current understanding of immune cor-
relates of protection against SARS-CoV-2
is limited but will be essential to enable the
development of SARS-CoV-2 vaccines and
other immunotherapeutic interventions. To
facilitate the preclinical evaluation of vaccine
candidates, we recently developed a rhesus
macaque model of SARS-CoV-2 infection
(9). In the present study, we constructed a set
of prototype DNA vaccines expressing various
forms of the SARS-CoV-2 spike (S) protein
and assessed their immunogenicity and pro-
tective efficacy against SARS-CoV-2 viral chal-
lenge in rhesus macaques.
Construction and immunogenicity of DNA
vaccine candidates
We produced a series of prototype DNA vac-
cines expressing six variants of the SARS-CoV-2
S protein: (i) full length (S), (ii) deletion of the
cytoplasmic tail (S.dCT) (10), (iii) deletion of
the transmembrane domain and cytoplasmic
tail reflecting the soluble ectodomain (S.dTM)
(10), (iv) S1 domain with a foldon trimerization
tag (S1), (v) receptor-binding domain with a
foldon trimerization tag (RBD), and (vi) a
prefusion-stabilized soluble ectodomain with
deletion of the furin cleavage site, two proline
mutations, and a foldon trimerization tag
(S.dTM.PP) (11–13) (Fig. 1A). Western blot
analyses confirmed expression in cell lysates
for all constructs and in culture supernatants
for the soluble S.dTM and S.dTM.PP constructs
(Fig. 1, B and C). Proteolytic cleavage of the
secreted protein was noted for S.dTM but not
S.dTM.PP, presumably as a result of mutation
of the furin cleavage site in S.dTM.PP.
We immunized 35 adult rhesus macaques
(6 to 12 years old) with DNA vaccines in the
following groups: S (N = 4), S.dCT (N = 4),
S.dTM (N = 4), S1 (N = 4), RBD (N = 4), S.dTM.
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Fig. 1. Construction of candidate DNA vaccines against SARS-
CoV-2. (A) Six DNA vaccines were produced expressing different
SARS-CoV-2 spike (S) variants: (i) full length (S), (ii) deletion of the
cytoplasmic tail (S.dCT), (iii) deletion of the transmembrane (TM)
domain and cytoplasmic tail (CT) reflecting the soluble
ectodomain (S.dTM), (iv) S1 domain with a foldon trimerization
tag (S1), (v) receptor-binding domain with a foldon trimerization tag
(RBD), and (vi) prefusion-stabilized soluble ectodomain with deletion
of the furin cleavage site, two proline mutations, and a foldon
trimerization tag (S.dTM.PP). Open squares depict foldon
trimerization tags; red lines depict proline mutations.
(B) Western blot analyses for expression from DNA vaccines
encoding S (lane 1), S.dCT (lane 2), S.dTM (lane 3), and S.dTM.
PP (lane 4) in cell lysates and culture supernatants using an
anti-SARS polyclonal antibody (BEI Resources). (C) Western blot
analyses for expression from DNA vaccines encoding S1 (lane 1)
and RBD (lane 2) in cell lysates using an anti–SARS-CoV-2 RBD
polyclonal antibody (Sino Biological).
Fig. 2. Humoral immune responses in vaccinated rhesus macaques. (A to
C) Humoral immune responses were assessed after immunization by (A) binding
antibody ELISA, (B) pseudovirus neutralization assays, and (C) live virus
neutralization assays. (D) Comparison of pseudovirus neutralization titers in
vaccinated macaques (all animals as well as the S and S.dCT groups), a cohort
of 9 convalescent macaques, and a cohort of 27 convalescent humans from
Boston, United States, who had recovered from SARS-CoV-2 infection.
NHP, nonhuman primates. (E) S- and RBD-specific antibody-dependent neutrophil
phagocytosis (ADNP), antibody-dependent complement deposition (ADCD),
antibody-dependent monocyte cellular phagocytosis (ADCP), and antibody-
dependent NK cell activation (IFN-g secretion, CD107a degranulation, and MIP-
1b expression) are shown. Radar plots show the distribution of antibody features
across the vaccine groups. The size and color intensity of the wedges indicate the
median of the feature for the corresponding group (blue depicts antibody
functions; red depicts antibody isotype, subclass, and FcgR binding). The principal
components analysis (PCA) plot shows the multivariate antibody profiles across
groups. Each dot represents an animal, the color of the dot denotes the group,
and the ellipses show the distribution of the groups as 70% confidence levels
assuming a multivariate normal distribution. In the dot plots above, red bars reflect
median responses, and dotted lines reflect assay limits of quantitation.
PP (N = 5), and sham controls (N = 10).
Animals received 5-mg DNA vaccines by the
intramuscular routewithout adjuvant atweeks 0
and 3. After the boost immunization at week 5,
we observed S-specific binding antibodies by
enzyme-linked immunosorbent assay (ELISA)
(Fig. 2A) and neutralizing antibodies (NAbs)
by both a pseudovirus neutralization assay (10)
(Fig. 2B) and a live virus neutralization assay
(14, 15) (Fig. 2C). As determined by ELISA, two
animals had binding antibodies at baseline,
which might reflect cross-reactivity of other
natural primate coronaviruses. NAb titers mea-
sured by the pseudovirus neutralization assay
correlated with NAb titers measured by the
live virus neutralization assay (P < 0.0001,R =
0.8052, two-sided Spearman rank-correlation
test; fig. S1). Moreover, NAb titers in the vac-
cinated macaques (median titer = 74; median
titer in the S and S.dCT groups = 170) were
comparable in magnitude to NAb titers in
a cohort of 9 convalescent macaques (me-
dian titer = 106) and a cohort of 27 con-
valescent humans (median titer = 93) who
had recovered from SARS-CoV-2 infection
(Fig. 2D).
S-specific and RBD-specific antibodies in
the vaccinated macaques included diverse
subclasses and effector functions, including
antibody-dependent neutrophil phagocytosis
(ADNP), antibody-dependent complement
deposition (ADCD), antibody-dependent mono-
cyte cellular phagocytosis (ADCP), and antibody-
dependent natural killer (NK) cell activation
[interferon-g (IFN-g) secretion, CD107a de-
granulation, and MIP-1b expression] (16) (Fig.
2E). A trend toward higher ADCD responses
was observed in the S and S.dCT groups,
whereas higher NK cell activation was ob-
served in the RBD and S.dTM.PP groups. A
principal components analysis of the func-
tional and biophysical antibody features
showed overlap of the different vaccine groups,
with more distinct profiles in the S and RBD
groups (Fig. 2E).
We also observed cellular immune responses
to pooled S peptides in most vaccinated
animals by IFN-g enzyme-linked immuno-
sorbent spot (ELISPOT) assays at week 5
(Fig. 3A). Intracellular cytokine staining as-
says at week 5 demonstrated induction of
S-specific IFN-g+ CD4+ and CD8+ T cell re-
sponses, with lower responses induced by
the shorter S1 and RBD immunogens (Fig.
3B). S-specific IL-4+ CD4+ and CD8+ T cell
responses were marginal (Fig. 3C), suggest-




At week 6, which was 3 weeks after the boost
immunization, all animals were challenged
with 1.2 × 108 virus particles (VPs) [1.1 × 104
plaque-forming units (PFUs)] of SARS-CoV-2,
administered as 1 ml by the intranasal route
and 1 ml by the intratracheal route. After
challenge, we assessed viral RNA levels by
reverse transcription polymerase chain reac-
tion (17) in bronchoalveolar lavage (BAL) and
nasal swabs (NS). Viral RNA was negative in
plasma, and animals exhibited onlymild clin-
ical symptoms. High levels of viral RNA were
observed in the sham controls, with a median
peak of 6.46 (range = 4.81 to 7.99) log10 RNA
copies/ml in BAL and a median peak of 6.82
(range = 5.96 to 7.96) log10 RNA copies/swab
in NS (fig. S2). Lower levels of viral RNAwere
observed in the vaccine groups (figs. S3 and
S4), including 1.92 and 2.16 log10 reductions
of median peak viral RNA in BAL and NS, re-
spectively, in S-vaccinated animals compared
with sham controls (P = 0.02 and 0.04, two-
sidedMann-Whitney tests) (fig. S5). Viral RNA
assays were confirmed by PFU assays, which
similarly showed lower infectious virus titers
in S-vaccinated animals compared with sham
controls (P = 0.04, two-sided Mann-Whitney
test) (fig. S5).
We speculated that a substantial fraction of
viral RNA in BAL and NS after challenge rep-
resented input challenge virus. Therefore,
we also assessed levels of subgenomic mRNA
(sgmRNA), which are believed to reflect viral
replication cellular intermediates that are not
packaged into virions, and thus putative rep-
licating virus in cells (18).High levels of sgmRNA
were observed in the sham controls (Fig. 4A)
with a median peak of 5.35 (range = 3.97 to
6.95) log10 sgmRNA copies/ml in BAL and
6.40 (range = 4.91 to 7.01) log10 sgmRNA
copies per swab in NS. Peak viral loads oc-
curred variably on days 1 to 4 after challenge.
Markedly lower levels of sgmRNA were ob-
served in the vaccine groups (Fig. 4, B and
C), including >3.1 and >3.7 log10 decreases
of median peak sgmRNA in BAL and NS, re-
spectively, in S-vaccinated animals compared
with sham controls (P = 0.03 and 0.01, two-
sided Mann-Whitney tests) (Fig. 4D). Re-
duced levels of sgmRNA were also observed
in other vaccine groups, including S.dCT, S1,
RBD, and S.dTM.PP, although minimal to no
protection was seen in the S.dTM group, con-
firming the importance of prefusion ectodo-
main stabilization, as reported previously
(13). Protection was generally more robust in
BAL compared with NS, particularly for the
less immunogenic constructs. A total of 8 of
25 vaccinated animals exhibited no detect-




The variability in protective efficacy in this
study facilitated an analysis of immune corre-
lates of protection. The log10 pseudovirus NAb
titer at week 5 inversely correlated with peak
Fig. 3. Cellular immune responses in vaccinated rhesus macaques.
At week 5 after immunization, cellular immune responses were
assessed by (A) IFN-g ELISPOT assays and (B) IFN-g+ and (C) IL-4+
intracellular cytokine staining assays for CD4+ and CD8+ T cells in
response to pooled S peptides. Red bars reflect median responses;
dotted lines reflect assay limits of quantitation.
log10 sgmRNA in both BAL (P < 0.0001, R =
−0.6877, two-sided Spearman rank-correlation
test) andNS (P = 0.0199,R = −0.4162) (Fig. 5A).
Similarly, the log10 live virusNAb titer atweek 5
inversely correlated with peak log10 sgmRNA
levels in bothBAL (P<0.0001,R=−0.7702) and
NS (P = 0.1006, R = −0.3360) (Fig. 5B). These
data suggest that vaccine-elicited serum NAb
titersmay be immune correlates of protection
against SARS-CoV-2 challenge. We speculate
that correlations were more robust with viral
loads in BAL comparedwith viral loads inNS,
due to intrinsic variability of collecting swabs.
The log10 ELISA titer at week 5 also inversely
correlated with peak log10 sgmRNA levels
in BAL (P = 0.0041, R = −0.4733) (fig. S6).
Vaccine-elicited ELISPOT responses (fig. S7),
CD4+ intracellular cytokine staining (ICS) re-
sponses (fig. S8), and CD8+ ICS responses (fig.
S9) did not correlate with protection.
We next explored the potential contribution
of other antibody effector functions to immune
correlates of protection. In addition to NAb
titers, S- and RBD-specific ADCD responses
inversely correlated with peak log10 sgmRNA
levels in BAL (Fig. 5C, top). Two orthogonal
unbiased machine learning approaches were
then used to define minimal combined corre-
lates of protection. A nonlinear random forest
regression analysis and a linear partial least
squares regression analysis showed that using
two features improved the correlations with
protection, such as RBD-specific FcgR2a-1 bind-
ing with ADCD responses or NAb titers with
RBD-specific IgG2 responses (Fig. 5C, bottom
left). Moreover, NAb titers correlatedwithmost
antibody effector functions, except for antibody-
mediated NK cell activation (Fig. 5C, bottom
right). Taken together, these data suggest that
NAbs have a primary role in protecting against
SARS-CoV-2, supported by certain innate im-
mune effector functions such as ADCD.
Finally, we compared antibody parameters
in vaccinated animals that were completely
protected (defined as no detectable sgmRNA
after challenge) with those in vaccinated ani-
mals that were partially protected (defined
as detectable sgmRNA after challenge). Log10
NAb titers (P = 0.0004, two-sided Mann-
Whitney test), RBD-specific ADCD responses
(P = 0.0001), S-specific RBD responses (P =
0.0010), and RBD-specific ADCP responses
(P = 0.0005) were higher in completely pro-




All animals exhibited anamnestic humoral and
cellular immune responses after challenge, in-
cluding increased ELISA titers (fig. S10), pseu-
dovirus NAb titers (fig. S11), live virus NAb
titers (fig. S12), and IFN-g ELISPOT responses
(fig. S13) on day 14 after challenge. These data
suggest that vaccine protection was probably
not sterilizing (including in the 8 of 25 animals
that had no detectable sgmRNA in BAL and
NS at any time point after challenge) but rather
was likelymediated by rapid virologic control
after challenge.
Discussion
A safe and effective SARS-CoV-2 vaccine may
be required to end the global COVID-19 pan-
demic. Several vaccine candidates have ini-
tiated clinical testing, and many others are in
preclinical development (19, 20). However, very
little is currently known about immune corre-
lates of protection and protective efficacy of
candidate SARS-CoV-2 vaccines in animal
models. In this study, we generated a series
of prototype DNA vaccines expressing var-
ious S immunogens and assessed protective
efficacy against intranasal and intratracheal
SARS-CoV-2 challenge in rhesus macaques.
We demonstrated vaccine protection with
substantial >3.1 and >3.7 log10 reductions in
median viral loads in BAL and NS, respec-
tively, in S-immunized animals compared
with sham controls. Protection was likely
Fig. 4. Viral loads in rhesus macaques challenged with SARS-CoV-2 virus.
Rhesus macaques were challenged via the intranasal and intratracheal routes
with 1.2 × 108 VPs (1.1 × 104 PFUs) of SARS-CoV-2. (A) Log10 sgmRNA
copies per milliliter or copies per swab (limit 50 copies) were assessed in
bronchoalveolar lavage (BAL) and nasal swabs (NS) in sham controls at multiple
time points after challenge. (B) Log10 sgmRNA copies per milliliter in BAL and
(C) log10 sgmRNA copies per swab in NS in vaccinated animals at multiple time
points after challenge. (D) Summary of peak viral loads in BAL and NS after
challenge. Peak viral loads occurred variably on days 1 to 4 after challenge. Red
lines reflect median viral loads. P values indicate two-sided Mann-Whitney tests.
tory syndrome (MERS) vaccine protection
in mice, ferrets, and macaques (10, 21–24).
Phase 1 clinical studies for SARS and MERS
vaccine candidates have also been conducted
(25), but these vaccines have not been tested
for efficacy in humans. Our data suggest
that vaccine protection against SARS-CoV-2
in macaques is feasible. We observed a marked
reduction of viral replication in both the up-
per respiratory tract and the lower respiratory
Fig. 5. Immune correlates of protection. (A and B) Correlations of (A)
pseudovirus NAb titers and (B) live NAb titers before challenge with log peak
sgmRNA copies per milliliter in BAL or log peak sgmRNA copies per swab in
nasal swabs after challenge. Red lines reflect the best-fit relationship between
these variables. P and R values reflect two-sided Spearman rank-correlation
tests. (C) The heatmap (top) shows the Spearman and Pearson correlations
between antibody features and log10 peak sgmRNA copies per milliliter in BAL
(*q < 0.05, **q < 0.01, ***q < 0.001 with Benjamini-Hochberg correction for
multiple testing). The bar graph (bottom left) shows the rank of the Pearson
correlation between cross-validated model predictions and data using the most
predictive combination or individual antibody features for partial least squares
regression (PLSR) and random forest regression (RFR). Error bars indicate
SEs. The correlation heatmap (bottom right) represents pairwise Pearson
correlations between features across all animals. (D) The heatmap (top) shows
the difference in the means of the z-scored features between the completely
protected and partially protected animals (**q < 0.01 with Benjamini-Hochberg
correction for multiple testing). The dot plots show differences in log10 NAb
titers, RBD-specific ADCD responses, S-specific ADCD responses, and RBD-
specific ADCP responses between the completely protected and partially
protected animals. P values indicate two-sided Mann-Whitney tests.
not sterilizing but instead appeared to be 
mediated by rapid immunologic control after 
challenge.
Our data extend the findings of previous 
studies on SARS and Middle East respira-
anatomic compartments will be necessary
for pandemic control, although protection in
the upper respiratory tract may be more
difficult to achieve. If this NAb correlate
proves generalizable across multiple vaccine
studies in both nonhuman primates and hu-
mans, then this parameter would be a simple
and useful benchmark for clinical develop-
ment of SARS-CoV-2 vaccines. Innate immune
effector functions such as ADCD may also
contribute to protective efficacy. In summary,
we demonstrate effective vaccine protec-
tion against SARS-CoV-2 in rhesus macaques
and define NAb titers as an immune corre-
late of protection, which will accelerate the
development of SARS-CoV-2 vaccines for
humans.
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tract with the optimal vaccines. By contrast, 
the less immunogenic vaccines, such as S.dTM, 
showed partial protection in BAL but essen-
tially no protection in NS. These data suggest 
that it may be easier to protect against lower 
respiratory tract disease than against upper 
respiratory tract disease. In the present study, 
optimal protection was achieved with the full-
length S immunogen in both the upper and 
lower respiratory tracts, and reduced protec-
tion was observed with soluble constructs and 
smaller fragments. Our study did not address 
the question of whether emerging mutations 
in the SARS-CoV-2 S sequence mediate escape 
from NAb responses induced by immuno-
gens designed from the Wuhan/WIV04/2019 
sequence.
Further research will need to address the 
durability of protective immunity and the 
optimal platforms for a SARS-CoV-2 vac-
cine for humans (26). Although our data are 
restricted to DNA vaccines, our findings 
may be generalizable  to other gene-based
vaccines as well, including RNA vaccines 
and recombinant vector-based vaccines. Ad-
ditional research should also evaluate vaccine 
immunogenicity and protective efficacy in 
older animals. Future studies should also 
address the question of enhanced respira-
tory disease, which may result from antibody-
dependent enhancement (27–29). Although 
our study was not designed to examine safety 
issues, it is worth noting that the DNA vac-
cines induced TH1 rather than TH2 responses,  
and we did not observe enhanced clinical 
disease even with the suboptimal vaccine 
constructs that failed to protect against 
infection.
We identified serum NAb titers, as mea-
sured by two independent assays (pseudovirus 
neutralization and live virus neutralization), 
as a significant correlate of protection against 
disease of both the lower and upper respira-
tory tracts. It is likely that protection in both
